Sevoflurane in Chronic Obstructive Pulmonary Disease Exacerbation (SEVOCOPD)

University Hospital Center (CHU)

Status

Terminated

Conditions

Invasive Mechanical Ventilation

COPD Exacerbation

Treatments

Drug: Propofol

Drug: Sevoflurane

Study type

Interventional

Funder types

Other

Identifiers

NCT03460015

9856

Details and patient eligibility

About

Prospective, open-label, single-center, study to investigate the effect of sevoflurane sedation compared to a propofol-controlled arm during COPD exacerbation requiring invasive mechanical ventilation in ICU.

Primary outcome measure:

Evolution of airway resistance before and after sevoflurane in COPD patients,

Secondary outcomes measures:

Respiratory mechanics (Maximum pressure, PEEPi and PEEPtot, trapped volume), Gas exchange by the help of blood gases, The heterogeneity of alveolar ventilation by electro-impedancemetry, Evolution of pulmonary inflammation, Trophicity and contractility of the diaphragm,

Enrollment

16 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria :

COPD exacerbation
Invasive mechanical ventilation and sedation for a planned duration of at least 24 hours
Consent
Age ≥ 18 years
Affiliation or beneficiary of a social security scheme

Exclusion Criteria :

Contraindication to the administration of sevoflurane (personal or family history of malignant hyperthermia, allergy or halogenated anesthetic accident, chronic myopathy, halogenated toxic hepatitis, uncontrolled intracranial hypertension, unexplained leukocytosis after anesthesia with a halogenated agent)
Contraindication to the administration of propofol (known hypersensitivity to propofol, soy, peanut or any of the excipients of the emulsion, antecedent of Propofol Related Infusion Syndrome)
Refusal of consent
Guardianship
Age < 18 years
Pregnant or lactating woman